On Monday, July 3, the next meeting of the Transparency Council.
The agenda includes:
Preparation of positions on drug evaluation:
- Vabysmo (farycymabum) under drug program B.70 "Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0)."
- Download this article in .pdf format
